AbCellera acquires Boston-based TetraGenetics


    The Vancouver-based biotech said TetraGenetics’s proprietary technology will help boost its capabilities to find antibodies. AbCellera paid US$12.5 million cash and may also make future payments based on various milestones, according to a filing with the U.S. Securities and Exchange Commission. (The Logic)

      Read this article for free

      By entering your e-mail you consent to receiving commercial electronic messages from The Logic Inc. containing news, updates, offers or promotions about The Logic Inc.’s products and services. You can withdraw your consent at anytime. Please refer to our privacy policy or contact us for more details.
      Already a subscriber?